Thursday, April 15, 2021
Home Life Style Health & Fitness Experimental Drug for Parkinson's Shows Progress

Experimental Drug for Parkinson’s Shows Progress

New drug for Parkinson's shows promise

An experimental drug has shown promise in treatment of debilitating movement problems in people with Parkinson’s disease. This is the latest health news.

The researchers investigated the effect of the drug NLX-112 on dyskinesia, a common side effect experienced by people with Parkinson’s who have been taking levodopa-based medications for several years. Levodopa is generally used as a dopamine replacement agent for the treatment of Parkinson’s.

The drug works by targeting serotonin cells inside the brain which are believed to contribute to the development of dyskinesia, by releasing dopamine in an erratic manner. It aims to reduce dyskinesia by decreasing the amount of dopamine the cells release, said the study published online in the journal Neuropharmacology.

The research was carried out by US-based biotech company Neurolixis with funding from Parkinson’s UK, a charity.

Parkinson's drug
The drug works by targeting serotonin cells inside the brain which are believed to contribute to the development of dyskinesia, by releasing dopamine in an erratic manner. (Representational Image). Pixabay

“This promising research on NLX-112 offers hope that we can find a treatment that can tackle dyskinesia, which can make everyday tasks, such as eating, writing and walking, extremely difficult,” said Arthur Roach, Director of Research at Parkinson’s UK.

“People with Parkinson’s tell us it is one of the most critical issues that impacts quality of life so we’re delighted that this project is progressing so positively,” Roach said.

Anyone can get Parkinson’s, young or old. Parkinson’s is what happens when the brain cells that make dopamine start to die. There are over 40 symptoms, from tremor and pain to anxiety. Some are treatable, but the drugs can have serious side effects. It gets worse over time and there’s no cure yet.

Around half of all people with Parkinson’s will experience dyskinesia after just five years of taking levodopa, and up to 80 per cent of people will experience it after ten years of taking the medication.

In this study, the drug NLX-112 was tested in monkeys with Parkinson’s-like symptoms. The monkeys had developed the side effect of dyskinesia in response to levodopa treatment in a similar way to many people with Parkinson’s.

The study looked at the effect of NLX-112 both on its own and in combination with levodopa, to understand how it impacted both dyskinesia and Parkinson’s symptoms.

The results showed that NLX-112 successfully reduced dyskinesia and crucially, did not significantly reduce the effectiveness of levodopa, which many other similar drugs do.

Also Read- 2 Experimental Drugs Fail to Prevent Alzheimer’s Disease

When NLX-112 was used on its own (without levodopa), it again improved movement problems.

These promising results suggest that NLX-112 has potential as a future treatment for not only reducing dyskinesia, but also for improving the movement symptoms of Parkinson’s, said the study. (IANS)

STAY CONNECTED

19,517FansLike
362FollowersFollow
1,773FollowersFollow

Most Popular

Top 7 Laptops You Should Buy For Programming

By Ankit Sharma Laptops have become ubiquitous today, and everyone -- from school kids to young adults, and from working professionals to home-makers uses laptops...

Tips To Start A Healthy Lifestyle

By Martin William Health is one of the most important assets of life and shouldn’t be compromised for anything. Unfortunately, it's sad to see that...

Why Doesn’t The Leaning Tower Of Pisa Fall Over?

BY- JAYA CHOUDHARY In 1990, the Italian government enrolled top engineers to secure Pisa’s iconic Leaning Tower. Various attempts to right the tower had been...

A Few Fascinating Facts About The Sparkling Diamond

Diamonds have an unmatched beauty, their enigmatic energy, or simply a legacy thats billions of years old captivates people all over the world. April...

A Guide For New-Age Art Collectors

Given the current exposure, Indian art is receiving, the projected turnover for the market will hold its ground, and further expand over the next...

“AahaarKranti”, A Mission Dedicated To Spreading Awareness About Nutrition

To eradicate malnutrition from the country which persists even in the 21st century, a group of nearly a dozen key private as well as...

AUM Of India’s Pension Schemes Is Increasing As More People Flock In

India's state-run pension schemes bucked the Covid-19 induced downtrend as the pandemic triggered an upsurge in new enrolments and sustained contributions. Assets Under Management (AUM)...

UPI Remained Most Preferred Payment Mode In India: Report

Digital transactions processed at physical touchpoints such as grocery stores, fuel stations, clothing & apparel, pharmacies, restaurants, and specialty retail together accounted for 80...

Recent Comments